Viroblock, a Geneva-based biotech focused on new antiviral drugs, raised a first round of funding. The company didn’t disclose financial details; its release is here. The round was led by private investor Peter Pfister, Fongit Seed Invest, and Initiative Capital Romandie.

The company is developing new ways for attacking “enveloped” viruses, whose DNA or RNA genomes are wrapped in some form of protein coat. A Viroblock official said in a statement that the funding will allow the company to move from Petri-dish experiments to animal tests.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.

Author
Topics